137 related articles for article (PubMed ID: 30387863)
21. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
22. Importance of target-mediated drug disposition for small molecules.
Smith DA; van Waterschoot RAB; Parrott NJ; Olivares-Morales A; Lavé T; Rowland M
Drug Discov Today; 2018 Dec; 23(12):2023-2030. PubMed ID: 29928850
[TBL] [Abstract][Full Text] [Related]
23. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
24. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
25. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
26. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
[TBL] [Abstract][Full Text] [Related]
27. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.
Grimm HP
J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050
[TBL] [Abstract][Full Text] [Related]
28. Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.
Yamazaki S; Shen Z; Jiang Y; Smith BJ; Vicini P
Drug Metab Dispos; 2013 Jun; 41(6):1285-94. PubMed ID: 23557746
[TBL] [Abstract][Full Text] [Related]
29. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.
Yan X; Chen Y; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):543-60. PubMed ID: 22926955
[TBL] [Abstract][Full Text] [Related]
30. Characterizing the Nonlinear Pharmacokinetics and Pharmacodynamics of BI 187004, an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Humans by a Target-Mediated Drug Disposition Model.
Yuan X; An G
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38652112
[TBL] [Abstract][Full Text] [Related]
31. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
[TBL] [Abstract][Full Text] [Related]
32. Asymptotic analysis of a TMDD model: when a reaction contributes to the destruction of its product.
Michalaki LI; Goussis DA
J Math Biol; 2018 Sep; 77(3):821-855. PubMed ID: 29675601
[TBL] [Abstract][Full Text] [Related]
33. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
Volz AK; Dingemanse J; Krause A; Lehr T
Pharm Res; 2019 Dec; 37(1):2. PubMed ID: 31823033
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of basic target-mediated drug disposition (TMDD) and ligand facilitated target removal (LFTR).
Peletier LA; Jansson-Löfmark R; Gabrielsson J
Eur J Pharm Sci; 2021 Jul; 162():105835. PubMed ID: 33848634
[TBL] [Abstract][Full Text] [Related]
35. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):17-26. PubMed ID: 28074395
[TBL] [Abstract][Full Text] [Related]
36. A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy Adults.
Wu N; Katz DA; An G
J Clin Pharmacol; 2021 Nov; 61(11):1442-1453. PubMed ID: 34110620
[TBL] [Abstract][Full Text] [Related]
37. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
Yan X; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):141-6. PubMed ID: 22215144
[TBL] [Abstract][Full Text] [Related]
38. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
[TBL] [Abstract][Full Text] [Related]
39. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
Yan X; Ruixo JJP; Krzyzanski W
AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
[TBL] [Abstract][Full Text] [Related]
40. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
